
Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes
Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes
Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes
Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes
Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes
CONCENTRATION
CONCENTRATION
CONCENTRATION
CONCENTRATION
CONCENTRATION
Semaglutide
Semaglutide
Semaglutide
Semaglutide
Semaglutide

15mg/3mL
15mg/3mL
15mg/3mL

15mg/3mL
PHARMACEUTICAL FORM
PHARMACEUTICAL FORM
PHARMACEUTICAL FORM
PHARMACEUTICAL FORM
PHARMACEUTICAL FORM




Injectable solution
Injectable solution
Injectable solution
Injectable solution
Injectable solution
1 vial 40 mg of Retatrutide (lyophilized powder)
1 vial 3 ml of bacteriostatic water
1 vial 40 mg of Retatrutide (lyophilized powder)
1 vial 3 ml of bacteriostatic water
1 vial 40 mg of Retatrutide (lyophilized powder)
1 vial 3 ml of bacteriostatic water




Efficacy
Semaglutide is a synthetic peptide and long-acting agonist of the glucagon-like peptide-1 (GLP-1) receptor, developed to improve glycemic control in patients with type 2 diabetes and to support weight management.
Its mechanism of action includes glucose-dependent stimulation of insulin secretion, suppression of glucagon release, delayed gastric emptying, and reduction of appetite.
Through GLP-1 receptor activation, Semaglutide enhances pancreatic β-cell function and improves metabolic parameters, leading to reductions in HbA1c and body weight.
Semaglutide is a synthetic peptide and long-acting agonist of the glucagon-like peptide-1 (GLP-1) receptor, developed to improve glycemic control in patients with type 2 diabetes and to support weight management.
Its mechanism of action includes glucose-dependent stimulation of insulin secretion, suppression of glucagon release, delayed gastric emptying, and reduction of appetite.
Through GLP-1 receptor activation, Semaglutide enhances pancreatic β-cell function and improves metabolic parameters, leading to reductions in HbA1c and body weight.
Semaglutide is a synthetic peptide and long-acting agonist of the glucagon-like peptide-1 (GLP-1) receptor, developed to improve glycemic control in patients with type 2 diabetes and to support weight management.
Its mechanism of action includes glucose-dependent stimulation of insulin secretion, suppression of glucagon release, delayed gastric emptying, and reduction of appetite.
Through GLP-1 receptor activation, Semaglutide enhances pancreatic β-cell function and improves metabolic parameters, leading to reductions in HbA1c and body weight.
| Dados | Finalidade | Descrição |
|---|---|---|
| Dados de Cadastro | Realizar o cadastro; Realizar identificação dos Usuários junto à Plataforma | Descrição detalhada dos dados de cadastro. |
| Dados de Atividade | Personalização da Plataforma de acordo com a experiência do usuário | Descrição detalhada dos dados de atividade. |
About
Semaglutida
About
Semaglutida
Semaglutide is a synthetic peptide and selective GLP-1 receptor agonist. It is indicated as an adjunct to diet and physical activity to improve glycemic control in adults with type 2 diabetes mellitus and to support long-term weight management.
Its mechanism includes glucose-dependent stimulation of insulin secretion, suppression of glucagon release, delayed gastric emptying, and appetite reduction. Across multiple clinical trials, semaglutide has consistently reduced HbA1c and body weight while maintaining a favorable safety profile.
Semaglutide is a synthetic peptide and selective GLP-1 receptor agonist. It is indicated as an adjunct to diet and physical activity to improve glycemic control in adults with type 2 diabetes mellitus and to support long-term weight management.
Its mechanism includes glucose-dependent stimulation of insulin secretion, suppression of glucagon release, delayed gastric emptying, and appetite reduction. Across multiple clinical trials, semaglutide has consistently reduced HbA1c and body weight while maintaining a favorable safety profile.
Indications
Indications
Indicated as an adjunct to diet and physical activity to improve glycemic control in adults with type 2 diabetes mellitus. It may also be considered for weight management in patients with comorbid obesity, based on clinical judgment.
Indicated as an adjunct to diet and physical activity to improve glycemic control in adults with type 2 diabetes mellitus. It may also be considered for weight management in patients with comorbid obesity, based on clinical judgment.
Indicated as an adjunct to diet and physical activity to improve glycemic control in adults with type 2 diabetes mellitus. It may also be considered for weight management in patients with comorbid obesity, based on clinical judgment.
Dosage
Dosage
Each vial contains 15 mg of semaglutide, reconstituted with 3 mL of bacteriostatic water for injection to yield a concentration of 5 mg/mL.
The recommended starting dose is 0.25 mg (0.05 mL) once weekly for 4 weeks to improve gastrointestinal tolerability, then increase to 0.5 mg (0.10 mL) once weekly. Based on individual clinical response and tolerability, the dose may be increased in 0.5 mg increments every 4 weeks, up to a maximum of 2.0 mg (0.40 mL) per week.
Dosage must be measured with a precision syringe and adjusted by a licensed healthcare provider.
Each vial contains 15 mg of semaglutide, reconstituted with 3 mL of bacteriostatic water for injection to yield a concentration of 5 mg/mL.
The recommended starting dose is 0.25 mg (0.05 mL) once weekly for 4 weeks to improve gastrointestinal tolerability, then increase to 0.5 mg (0.10 mL) once weekly. Based on individual clinical response and tolerability, the dose may be increased in 0.5 mg increments every 4 weeks, up to a maximum of 2.0 mg (0.40 mL) per week.
Dosage must be measured with a precision syringe and adjusted by a licensed healthcare provider.


| Dados de Cadastro | Realizar o cadastro; Realizar identificação dos Usuários junto à Plataforma | Descrição detalhada dos dados de cadastro. |
|---|---|---|
| Dados de Atividade | Personalização da Plataforma de acordo com a experiência do usuário | Descrição detalhada dos dados de atividade. |
Drug Interactions
Drug Interactions
Semaglutide may delay gastric emptying, which could affect the absorption of concomitantly administered oral medications. Although no clinically relevant interactions have been consistently observed in clinical trials, caution is advised, especially with drugs that require rapid gastrointestinal absorption or have a narrow therapeutic index.
Semaglutide may delay gastric emptying, which could affect the absorption of concomitantly administered oral medications. Although no clinically relevant interactions have been consistently observed in clinical trials, caution is advised, especially with drugs that require rapid gastrointestinal absorption or have a narrow therapeutic index.
Semaglutide may delay gastric emptying, which could affect the absorption of concomitantly administered oral medications. Although no clinically relevant interactions have been consistently observed in clinical trials, caution is advised, especially with drugs that require rapid gastrointestinal absorption or have a narrow therapeutic index.
Adverse Reactions
Adverse Reactions
Gastrointestinal adverse events are the most frequently reported with semaglutide use. Nausea, vomiting, and diarrhea are commonly observed, particularly during the dose-escalation phase. These events are typically mild to moderate in severity and tend to decrease over time with continued treatment and proper titration.
Gastrointestinal adverse events are the most frequently reported with semaglutide use. Nausea, vomiting, and diarrhea are commonly observed, particularly during the dose-escalation phase. These events are typically mild to moderate in severity and tend to decrease over time with continued treatment and proper titration.
Gastrointestinal adverse events are the most frequently reported with semaglutide use. Nausea, vomiting, and diarrhea are commonly observed, particularly during the dose-escalation phase. These events are typically mild to moderate in severity and tend to decrease over time with continued treatment and proper titration.
Storage
Storage
Store the lyophilized powder at room temperature, below 30°C. Do not freeze. Protect from light and moisture.
Store the lyophilized powder at room temperature, below 30°C. Do not freeze. Protect from light and moisture.
Store the lyophilized powder at room temperature, below 30°C. Do not freeze. Protect from light and moisture.
After reconstitution with bacteriostatic water, store the solution in a refrigerator at 2°C to 8°C. Use within 21 days. Discard any unused reconstituted solution after this period.
After reconstitution with bacteriostatic water, store the solution in a refrigerator at 2°C to 8°C. Use within 21 days. Discard any unused reconstituted solution after this period.
After reconstitution with bacteriostatic water, store the solution in a refrigerator at 2°C to 8°C. Use within 21 days. Discard any unused reconstituted solution after this period.
Marso SP, et al.
Liraglutide and Semaglutide in Patients with Type 2 Diabetes – Cardiovascular Outcomes.
N Engl J Med. 2016;375(4):311–322.
DOI: 10.1056/NEJMoa1607141
Blundell J, et al.
Appetite control and weight loss with GLP-1 receptor agonists: Semaglutide and Liraglutide.
Diabetes Obes Metab. 2017;19(8):954–962.
DOI: 10.1111/dom.12970
Wilding JPH, et al.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
N Engl J Med. 2021;384(11):989–1002.
DOI: 10.1056/NEJMoa2032183
Marso SP, et al.
Liraglutide and Semaglutide in Patients with Type 2 Diabetes – Cardiovascular Outcomes.
N Engl J Med. 2016;375(4):311–322.
DOI: 10.1056/NEJMoa1607141
Blundell J, et al.
Appetite control and weight loss with GLP-1 receptor agonists: Semaglutide and Liraglutide.
Diabetes Obes Metab. 2017;19(8):954–962.
DOI: 10.1111/dom.12970
Wilding JPH, et al.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
N Engl J Med. 2021;384(11):989–1002.
DOI: 10.1056/NEJMoa2032183
Marso SP, et al.
Liraglutide and Semaglutide in Patients with Type 2 Diabetes – Cardiovascular Outcomes.
N Engl J Med. 2016;375(4):311–322.
DOI: 10.1056/NEJMoa1607141
Blundell J, et al.
Appetite control and weight loss with GLP-1 receptor agonists: Semaglutide and Liraglutide.
Diabetes Obes Metab. 2017;19(8):954–962.
DOI: 10.1111/dom.12970
Wilding JPH, et al.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
N Engl J Med. 2021;384(11):989–1002.
DOI: 10.1056/NEJMoa2032183
Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.
Helpful links
Find your local office
USA
Germany
Latin America
© 2025 Safe Pro Labs. All rights reserved.
Data Privacy
Cookie Privacy
Cookie Settings
Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.
Helpful links
Find your local office
USA
Germany
Latin America
© 2025 Safe Pro Labs. All rights reserved.
Data Privacy
Cookie Privacy
Cookie Settings
Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.
Helpful links
Find your local office
USA
Germany
Latin America
© 2025 Safe Pro Labs. All rights reserved.
Data Privacy
Cookie Privacy
Cookie Settings
Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.
Helpful links
Find your local office
USA
Germany
Latin America
© 2025 Safe Pro Labs. All rights reserved.
Data Privacy
Cookie Privacy
Cookie Settings
Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.
Helpful links
Find your local office
USA
Germany
Latin America
© 2025 Safe Pro Labs. All rights reserved.
Data Privacy
Cookie Privacy
Cookie Settings
Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.
Helpful links
Find your local office
USA
Germany
Latin America
© 2025 Safe Pro Labs. All rights reserved.
Data Privacy
Cookie Privacy
Cookie Settings